Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Next Previous
X
Search
Trial Profile

Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Mitoxantrone; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jul 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 10 Dec 2012 Primary endpoint 'Event-free-survival-rate' has not been met.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top